Assessing the Impacts of a Tethered Educational Approach in Closing the Gaps in Clinician-Patient Communication and Individualized Dosing in Myasthenia Gravis
Vandana Gupta1, Carole Drexel1, Meridith O'Connor2, Evan Greene3, Pushpa Narayanaswami4, James Howard5
1PlatformQ Health, 2Myasthenia Gravis Foundation of America, 3Patient with MG, 4Harvard Medical School, 5University of North Carolina at Chapel Hill
Objective:
To evaluate the impact of tethered education for clinicians (HCPs) and patients/caregivers (P/Cs) on bridging gaps in communication to facilitate individualized dosing with new therapies for myasthenia gravis (MG).
Background:
In 2019, the FDA issued guidance for individualized dosing of medications to reduce risk of adverse events while optimizing therapeutic response. Clinical trials have shown that FcRn antagonists for MG are suitable options for this approach.
Design/Methods:
One 60-minute activity for P/Cs and one 60-minute CME activity for HCPs were launched in October 2023 and remained online for one year. Prior to the education, patients and HCPs were surveyed to assess existing gaps in communication. Test questions to evaluate knowledge, competence and practice behavior were administered before and after the education. Chi-square tests compared paired responses (P < .05; pre/post).
Results:
1265 HCPs and 1062 P/Cs participated in the activities. The pre-education survey data showed that 31% of HCPs reported being unsure of how to implement individualized dosing. Participation significantly (P < .01) enhanced knowledge of the FDA’s guidance (32% pre vs 51% post), and data supporting the use of individualized dosing with FcRn antagonists (48% pre vs 63% post). In the pre-education survey, 55% of P/Cs reported having not discussed individualized dosing with their HCPs. After the education, 92% of P/Cs felt empowered to discuss treatment options and 72% found the activity effective in increasing their knowledge of individualized dosing.
Conclusions:
Data support the positive impact of tethered education for HCPs and P/Cs in preparing them for the evolving management of MG and empowering P/Cs to participate in shared decision-making.
Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff.